The future is here. It's just not widely distributed yet.
—William Gibson
To answer the question of what's going to be hot in 2007, we need only look at the important advances in 2006.
Listed below are my top infectious disease developments from the prior year, which may have an impact on our practice in the coming year:
▸ Should we still be concerned about meningitis in the infant aged 2–24 months who has fever without a source? The good news is that overall rates of pneumococcal invasive disease are reduced compared to the pre-pneumococcal vaccine era, with the most significant reduction in the number of cases of occult bacteremia. However, we saw more cases of pneumococcal meningitis last year than in any other year in the last decade in our institution, almost all caused by nonvaccine serotypes. Continue to be vigilant in assessing the febrile infant without localizing findings, and carefully document immunization status to identify the underimmunized.
▸ Have we come to a new era in evaluation and management of pediatric urinary tract infection? For about 25 years, the recommendation has been that a voiding cystourethrogram be done after the first febrile UTI, but this has not been substantiated by current studies. Who should have imaging? Those who fail to respond after 72 hours of effective antibiotics, those infected with an unusual organism, those in whom close follow-up of the patient is not possible, those with abnormal urine stream or abdominal mass, and those with recurrence of a febrile UTI. The utility of prophylactic antibiotics to prevent recurrence of a febrile UTI or renal scarring is not known; some data suggest prophylaxis is not necessary. The knowledge that the risk of urosepsis is highest in youngest infants and recurrence is highest in the first 6 months after a UTI should be factored in when making the decision concerning prophylaxis. Look for the upcoming American Academy of Pediatrics policy, which will fully delineate these guidelines.
▸ Will rotavirus epidemiology change, now that the new vaccine has been implemented? Virtually every child is infected with rotavirus by 24 months of age; two-thirds of children are infected more than once. It is estimated that approximately 1 in 17 children will require an emergency department visit and approximately 1 in 65 children will require hospitalization. If the vaccine successfully eliminates 98% of severe cases, the impact on hospitalizations should be dramatic. The vaccine is given orally, with the first dose given between 6 and 12 weeks of age and two additional doses administered at 4- to 10-week intervals. All three doses should be completed before a child reaches 32 weeks of age. This restrictive timing of the immunization schedule has proved problematic, however, and full implementation may take another year or more.
▸ Should we remove a vaccine-preventable infection from the eradicated list? The resurgence of mumps in 2006 was unexpected. Approximately 5,000 cases were reported starting in December 2005, many occurring in individuals with a history of two doses of vaccine. This would not be unexpected in a highly immunized population, but the percentage of such cases still seems high to me and is not totally explained. The Advisory Committee on Immunization Practices now has redefined evidence of mumps immunity. Practitioners should ensure that preschool children and adults not at high risk have had one dose of a live mumps virus vaccine, and that two doses have been given for children in grades K-12 and adults at high risk (for example, persons who work in health care facilities, international travelers, and students at post-high school educational institutions). Immunity can be assumed for those who were born before 1957, have documentation of physician-diagnosed mumps, or laboratory evidence of immunity.
▸ What's new in influenza immunization? Those of you in practice who have struggled with obtaining influenza vaccine for your at-risk pediatric patients are probably wondering how we will ever improve the current distribution system and whether school-based immunization programs will be feasible in the future. A recent New England Journal of Medicine article sheds some light on the matter. (See story, page 4.) Investigators at the University of Maryland in Baltimore used intranasal live attenuated virus vaccine in a school-based immunization strategy to see if it reduced outcomes related to influenzalike illness (ILI). Vaccinated children were less likely to become ill, and ILI in adults in the same household also was reduced. There were lower absentee rates for flulike illness among the children, fewer lost workdays among parents, and a reduced rate of use of health care. Sounds good, but we may still be some years away from a universal program targeting flu in school-age children.